MiNK Therapeutics shared on LinkedIn:
“MiNK Therapeutics has been awarded a NIAID grant to advance its allogeneic iNKT cell therapy for patients undergoing stem cell transplant, with the goal of reducing complications such as GvHD.
This non-dilutive funding supports collaborative research with the University of Wisconsin.”
